MLTX

MoonLake Immunotherapeutics is a biotechnology company within the healthcare sector. The company has a market capitalization of $792.78 million and employs approximately 100 individuals. The company's financial health is marked by significant losses, with a net income of -$210,495,520 (TTM) and EBITDA of -$226,967,360. Additionally, MoonLake Immunotherapeutics reported free cash flow of -$117,383,136, indicating substantial outlays. The company maintains a strong liquidity position, with $380.48 million in cash reserves but also has debt totaling $75.73 million. Key financial metrics include return on equity (ROE) and return on assets (ROA), which are -54.3% and -30.7%, respectively. MoonLake Immunotherapeutics' valuation context is characterized by a negative forward P/E ratio of -3.13, suggesting that the market has discounted future earnings expectations. The company's price to book ratio stands at 2.47, while other valuation metrics such as price to sales and EV/EBITDA are not applicable or reported as negative (-2.02). Dividend information is not available.